Financial Performance Highlights
Q2 FY27 Consolidated Performance
- Revenue from Operations: INR 201 crore (66.5% increase YoY from INR 120 crore in Q2 FY26; 6.6% increase QoQ from Q1 FY27)
- EBITDA: INR 26.96 crore (142% increase YoY)
- EBITDA Margin: 13.25% (vs 9% in Q2 FY26, 420 bps improvement)
- Net Profit: INR 14.89 crore (610% increase YoY from INR 2 crore)
- Earnings Per Share: INR 12.78 (vs INR 1.91 in Q2 FY26)
H1 FY27 Consolidated Performance
- Revenue from Operations: INR 390 crore (44% increase YoY)
- EBITDA: INR 59.56 crore (157% increase YoY)
- EBITDA Margin: 15.15% (vs 8.45% in H1 FY26, 670 bps improvement)
- Net Profit: INR 33.92 crore (623% increase YoY)
Business Segment Performance
Blue Pigments (Phthalocyanine) Business:
- Extremely strong quarter with improvement on every key measure
- Revenue growth of ~47% in H1 FY27 over H1 FY26
- Driven by strong supplier relationships, procurement structure, energy efficiencies, and cost discipline
- Management confident of sustaining 13-15% EBITDA margins long-term
- Q3 typically sees softness due to global inventory tightening by export customers
- Q3 FY27 expected to be significantly better than Q3 FY26
AZO Pigments Business:
- Challenging Q2 with performance below expectations
- Q2 Revenue: INR 28.82 crore
- H1 Revenue: INR 47.35 crore
- Volumes grew but pricing remains tough with competitive pressure
- Business is EBITDA positive and cash positive
- Current utilization: 70-75%
- Focus on winning larger customers, improving product quality, and reducing production costs
- H2 FY27 expected to be better than H1 FY27
- PBT breakeven target for FY27 remains achievable
API Business (Atlas Life Sciences):
- Revenue increased ~33% in H1 FY27 over H1 FY26
- Volumes have grown at ~18% annually for past 3 years
- Price pressure continued to hold back performance
- Business is EBITDA positive and cash positive
- CEP (Certificate of Suitability) approval expected by March 2027 (possibly earlier)
- Current utilization: Odhav facility ~95%; Chhatral facility ~40%
- H2 FY27 expected to show improved performance with easing price pressures
Balance Sheet and Capital Allocation
- Strong cash generation enabled reduction of gross borrowings by ~INR 49 crore
- Deleveraging pace faster than expected since borrowing INR 200 crore
- Lower debt reducing finance costs and providing considerable headroom
- Company evaluating opportunities for next phase of growth (acquisitions, capacity expansion, or new projects)
- Disciplined approach to capital allocation with focus on return on capital employed
- Balance sheet described as strongest in company's history
- Targeting debt-to-EBITDA below 1x and net worth-to-debt of 0.15x-0.20x
Volume Data (Provided by CFO Maulik Shah)
Blue Business:
- H1 FY27: 4,691 tons vs 4,190 tons in H1 FY26
- Q2 FY27: 2,357 tons vs 1,748 tons in Q2 FY26
AZO Business:
- H1 FY27: 915 tons vs 907 tons in H1 FY26
- Q2 FY27: 546 tons vs 497 tons in Q2 FY26
API Business:
- H1 FY27: 196 tons vs 149 tons in H1 FY26
- Q2 FY27: 99 tons vs 78 tons in Q2 FY26
Strategic Outlook and Guidance
- Company targeting INR 900-1,000 crore revenue in next few years
- H1 FY27 annualizes to ~INR 780 crore revenue
- Growth expected from increased utilization of existing capacities with minimal CAPEX
- AZO capacity can be increased by 1.5 tons with INR 10-15 crore investment when utilization reaches 85%
- API business has significant room for utilization improvement (currently ~40% at Chhatral)
- CEP approval expected to open European and semi-regulated markets, improving realizations
- Company working on 8-10 additional API products including Levosulpiride, Amisulpride, and Phenylephrine
- Management believes structural improvements will sustain performance beyond current period
Raw Material and Pricing Environment
- Q1 included some inventory gains; Q2 is cleaner quarter without such benefits
- Raw material prices have been volatile with recent uptrend due to geopolitical factors
- Company maintains just-in-time inventory (approximately 2 weeks)
- Strong supplier relationships help manage volatility better than competitors
- Company positioned to perform well during volatile periods